BREAST CANCER

Fam-trastuzumab deruxtecan-nxki has been approved by the FDA for the treatment of adult patients with unresectable or HER2-positive metastatic breast cancer who have received a prior anti-HER2- based regimen.

Combination of ribociclib plus fulvestrant achieved a median overall survival of 67.6 months in the first-line setting for patients with postmenopausal, hormone receptor-positive, human epidermal growth factor receptor-2 negative advanced or metastatic breast cancer.

Treatment with the combination of odetiglucan or Imprime PGG and pembrolizumab had begun in patients with metastatic hormone-refractory breast cancer who are enrolled in a phase 2 clinical trial.

Jamie Brett, resident in internal medicine at Massachusetts General Hospital, discusses the effectiveness of CDK4/6 for patients with hormone receptor-positive metastatic breast cancer (MBC) with ESR1 mutations and fusions.

Participants of a live, virtual case-based event discussed different scenarios for treatment of a patient with BRCA and PD-L1 negative, metastatic triple-negative breast cancer. Vote in the polls on what you would have chosen if this was your patient.

During a case-based roundtable event, Kevin Kalinsky, MD, MS, discussed clinical typing of patients with breast cancer and the results of trials of therapies for patients with HR-positive, HER2-negative breast cancer.

In an interview with Targeted Oncology, William J. Gradishar, MD, discussed the current landscape of caring for patients with advanced breast cancer.

In season 3, episode 3 of Targeted Talks, William J. Gradishar, MD, discusses the latest version of the NCCN Clinical Practice Guideline for managing early-stage breast cancer.

FDA fast track designation has been granted to cell-based immunotherapy Bria-IMT for the treatment of patients with metastatic breast cancer.

Pertuzumab combined with trastuzumab, and docetaxel revealed comparable survival outcomes with previous studies of patients with metastatic breast cancer, including the CLEOPATRA trial.

According to new data, different dosing strategies of elimusertib for advanced solid tumors with ATM alterations and other DNA damage repair gene defects has demonstrated early efficacy.

According to Tanjina Kader, PhD, 12% of patients in the cohort who developed new, independent primary tumors raised the question of whether using these genetic biomarkers for prediction of recurrence is a good idea.

Part 2 of the phase 1/2 trial investigating LUT014, a topical agent for radiation-induced dermatitis in patients with breast cancer, completed its enrollment of 20 patients.

Lee Schwartzberg, MD, discusses important questions that have been raised due to the positive results of pembrolizumab immunotherapy for patients with triple-negative breast cancer.

The NCCN recommendations concerning the management of patients with TNBC have been updated for various settings, including early, recur- rent and unresectable, BRCA1/2-mutated, and high-risk triple-negative breast cancer.

Charles Geyer, MD, discusses olaparib for the treatment of patients with BRCA-positive, HER2-negative high-risk early breast cancer as evaluated in the OlympiA study.

A recent study found no difference in invasive disease–free survival between patients with HER2-negative breast cancer who took a full-strength aspirin daily and those who did not.

During a Targeted Oncology case-based roundtable event, Martin Dietrich, MD, PhD, discussed the MonarchE trial of abemaciclib and the agent's use in high-risk, early-stage breast cancer.

In an interview with Targeted Oncology, Charles Geyer, MD, discussed the data from the OlympiA clinical trial and how adjuvant olaparib could impact the treatment of BRCA-positive, HER2-negative breast cancer and other BRCA-positive women’s cancers.

During a Targeted Oncology case-based roundtable event, Claudine Isaacs, MD, discussed treatment options for a patient with triple-negative breast cancer whose condition worsened after first-line gemcitabine plus carboplatin.

Three and a half-year follow-up in the OlympiA trial showed continued survival improvement and underscores the vitality of germline BRCA testing.

Heather McArthur, MD; Massimo Cristofanilli, MD, FACP; Sunil Badve, MD, FRCPath; and Joyce O’Shaughnessy, MD, comment on the role of preoperative endocrine therapy in HR-positive high-risk breast cancer.

Joyce O’Shaughnessy, MD, reviews the case of a 42-year-old woman with node-positive, HR-positive high-risk breast cancer and discusses clinical data from the POETIC and ADAPT clinical trials.

An update from the phase 2 AMEERA-3 clinical trial shows that amcenestrant does not improve progression-free survival in ER-positive, HER2-negative breast cancer.

The FDA approved the BRACAnalysis CDx test for use as a companion diagnostic with adjuvant olaparib to identify patients with germline BRCA-mutated for patients with HER2 negative, high-risk early-stage breast cancer.